Company news
Sareum Holdings plc news in 2018
Sareum Holdings plc's news releases, calls and decks from 2018, newest first.
Amendment to Preclinical Efficacy Announcement
November 30, 2018
Preclinical Efficacy for Immunotherapy Combination
November 30, 2018
Preclinical Data for SRA737 in Ovarian Cancer
November 15, 2018
AGM NOTICE
November 14, 2018
Directorate Change
November 13, 2018
Sierra Oncology Q3 2018 Results
November 8, 2018
Completion of Placing
October 26, 2018
Final results for the year ended 30 June 2018
October 1, 2018
Notice of Results
September 27, 2018
TYK2/JAK1 selected for certain cancers
September 26, 2018
Pre-Close Trading Statement
September 11, 2018
Selection of TYK2/JAK1 for autoimmune diseases
September 10, 2018
Sareum notes Sierra Oncology Q2 2018 Results
August 9, 2018
Notification of PCA Shareholding
July 11, 2018
Advisers
June 15, 2018
Sareum regains rights to Aurora+FLT3 inhibitors
May 31, 2018
SRA737 trial update in Sierra Oncology Q1 Results
May 10, 2018
Sareum to Present at BioTrinity 2018 in London
April 24, 2018
AACR 2018 Update
April 17, 2018
Late-breaker abstract for SRA737 accepted for AACR
March 15, 2018
Interim Results
March 13, 2018
Sierra Oncology expands SRA737 development program
February 27, 2018
Preclinical synergy of sra737 and PARP inhibitor
February 22, 2018
Notice of Interim Results
February 13, 2018